HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serruys, P. W. Search for Related Content PubMed PubMed Citation Articles by Serruys, P. W.

Actinomycin-eluting stent for coronary revascularization

A randomized feasibility and safety study: The ACTION trial

Patrick W. Serruys, MD, PhD, FACC^*,*, John A. Ormiston, MD, Georgios Sianos, MD, PhD^*, J. Eduardo Sousa, MD, Eberhard Grube, MD, Peter den Heijer, MD^||, Pim de Feyter, MD^*, Pawel Buszman, MD^¶, Albert Schömig, MD^#, Jean Marco, MD^**, Lech Polonski, MD^¶, Leif Thuesen, MD, Andreas M. Zeiher, MD, J.H. Nicholas Bett, MD, Maarten J. Suttorp, MD^||||, Helmut D. Glogar, MD^¶¶, Mark Pitney, MD^##, Gerard T. Wilkins, MD^***, Robert Whitbourn, MD, Susan Veldhof, RN, Karine Miquel, PhD, Rachel Johnson, BA, Leslie Coleman, DVM, Renu Virmani, PhD ACTION Investigators

^* Erasmus Medical Center, Rotterdam, The Netherlands
Green Lane Hospital, Auckland, Australia
Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
Krankenhaus Siegburg, Siegburg, Germany
^|| Amphia Ziekenhuis, Breda, The Netherlands
^¶ Silesian Heart Disease Center, Katowice, Poland
^# Deutsches Herzzentrum München, Munich, Germany
^** Clinique Pasteur, Toulouse, France
Skejby Syghus, Aarhus, Denmark
Klinikum de J. W. Goethe Universität, Frankfurt, Germany
Prince Charles Hospital, Chermside, Australia
^|||| Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands
^¶¶ Allgemeines Krankenhaus de Stadt Wien, Vienna, Austria
^## Prince of Wales Hospital, Sydney, Australia
^*** Dunedin Hospital, Dunedin, New Zealand
St. Vincent's Hospital, Melbourne, Australia
Guidant Corporation, Diegim, Belgium
Armed Forces Institute of Pathology, Washington, DC

View larger version (30K): [in a new window]   Figure 1 Kaplan-Meier estimates of survival free of repeated target site revascularization up to 365 days among patients who received actinomycin-eluting 2.5 and 10 µg/cm2 stents and those who received the metallic stent. The rate of event-free survival was significantly higher in the control stent group than in the actinomycin stent groups (p < 0.05 by both the Wilcoxon and log-rank tests). Solid circles = control (n = 104); open circles = drug-coated, 2.5 µg/cm2 drug-eluting stent (n = 120); squares = drug-coated, 10 µg/cm2 drug-eluting stent (n = 119).